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1. Introduction 
The term “Metabolic Syndrome” is generally used to indicate a clinical entity of substantial 
heterogeneity, represented by the co-occurrence of hypertension, impaired glucose 
tolerance, atherogenic dyslipidemia, central fat accumulation, insulin resistance, as well as 
prothrombotic and inflammatory states[1]. This multiple metabolic and cardiovascular 
disorders clusters together in the same individual more often than might be expected by 
chance, leading to an increased probability of suffering from cardiovascular disease and 
type 2 diabetes mellitus[2], [3].  
Notwithstanding the controversial concept[4], data from large prospective population-based 
studies, such as the Framingham offspring study[5], the Botnia study[2], the Kuopio 
Ischemic heart Disease study[3], the Italian study [6], and the Atherosclerosis Risk in 
Communities (ARIC) study[7], [8], confirmed that the presence of the metabolic syndrome 
was significantly associated with an increased risk of cardiovascular disease morbidity and 
mortality, thus providing substantial support for the metabolic syndrome hypothesis[1]. 
One important justification cited for the utility of the syndrome is that it changed medical 
perspective from a single-risk factor to the multiple-risk factors paradigm [9], [10].  
During the last decade, this multiplex cardiometabolic disorder has progressively become 
a major worldwide public health problems, because of its association with increased risk 
of type 2 diabetes mellitus, atherosclerotic cardiovascular disease and all-cause 
mortality[2], [3], [1]. More than 100 million individuals suffer from this syndrome in the 
world. this number is set to increase rapidly, fuelled by the increase in obesity and 
diabetes epidemics[11]. The pathogenesis of the metabolic syndrome is complex and so far 
incompletely understood but the interaction of obesity, sedentary lifestyle, dietary, 
environmental and genetic factors are known to contribute to its development[12], [13], 
[14]. 
This chapter constitutes a review of the state-of-the-art of the metabolic syndrome, as 
regards the historical evolution of the concept, the debated key points and the evolution 
towards a new concept of global cardiometabolic risk. The last section provides an overview 
of the worldwide epidemiology of the metabolic syndrome, in terms of prevalence variation 
and determinants.  
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2. Historical evolution of the metabolic syndrome concept 
Regardless of the disagreement about who first described the metabolic syndrome in the 
medical literature, its basic concept existed for at least 80 years[15]. According to a group of 
researchers[11], the constellation of metabolic disturbances was initially described in 1920s 
by Kylin, and later by Vague in 1947. The latter drew the attention to upper body adiposity 
(android or male-type obesity), as a metabolic abnormality commonly associated with type 2 
diabetes and cardiovascular disease [16,17]. However, the frequent simultaneous presence 
of obesity, hypertension, diabetes and hyperlipidemia was described in 1965 by Avogaro et 
al, and then by Haller et al in 1977, who described their association with atherosclerosis[11]. 
Ten years later, the clinical importance of the syndrome was highlighted by Reaven who 
introduced the concept of Syndrome X, as a clustering of disturbances in glucose and insulin 
metabolism, dyslipidemia and hypertension. Reaven suggested that insulin resistance was a 
fundamental “disorder” associated with a set of metabolic abnormalities which not only 
increased the risk of type 2 diabetes but also contributed to the development of 
cardiovascular disease before the appearance of hyperglycemia. He emphasized that insulin 
resistance was at the centre of a cluster of metabolic abnormalities, which include 
hypertriglyceridemia, low high-density lipoprotein (LDL) cholesterol level, increased 
glycemia, and elevated blood pressure[13].  
Following this early conceptual contribution, numerous studies have confirmed that insulin 
resistance was indeed associated with metabolic abnormalities that increase the risk of both 
diabetes and cardiovascular disease [18,19]. Syndrome X was also called Reaven’s 
Syndrome, Insulin Resistance Syndrome, deadly quartet, and is now widely known as 
metabolic syndrome. A later key conceptual advance was the recognition of the central role 
of abdominal obesity [20] in the diagnosis of the metabolic syndrome, and its introduction 
as a clinically easy-measurable entity. This second hallmark put the abdominal obesity on 
the front line to diagnose the metabolic syndrome.  
3. Debated key points 
After a plethora of international publications, the metabolic syndrome concept is still ill-
defined with many unanswered questions[11], [21]. So far, evidence-based outcomes 
concerning the components and cut-off values are limited and based principally on expert 
consensus[22]. 
3.1 Diversity of definitions  
During the last decade, several definitions of the metabolic syndrome were suggested by a 
number of expert groups. Although these definitions were similar in their focus on basic 
criteria as obesity, dyslipidemia, hyperglycemia, and hypertension, substantial differences 
remained concerning the insulin resistance.  
3.1.1 WHO definition 
In an attempt to provide a tool for clinicians and researchers, the “WHO Working Group on 
Diabetes” proposed a set of criteria to define the metabolic syndrome [23]. The consensus was 
published on the WHO website in 1999, but reported clearly that the definition would be 
www.intechopen.com
 
Cardiometabolic Syndrome 
 
163 
modified as new information became available about the components and their predictive 
power. The WHO definition, stated that diabetes type 2 or impaired glucose tolerance (IGT), 
together with at least 2 of 4 other factors (hypertension, hyperlipidemia, obesity and 
microalbuminuria) define the metabolic syndrome. In case of normal glucose tolerance, the 
evidence of insulin resistance is needed; this is defined as the lowest quartile of measures of 
insulin sensitivity. The definition of obesity is based either on overall obesity assessed by body 
mass index (BMI), or on central obesity assessed by waist-to-hip ratio (WHR)[23] (Table 1).  
 
WHO definition of the metabolic syndrome 1999[23] 
Glucose intolerance, Impaired Glucose Tolerance (IGT) or Diabetes mellitus and/or insulin 
resistance together with two or more of the following criteria listed below: 
1. Obesity: BMI > 30 kg/m2 and / or Waist-to-hip ratio > 90 cm in men or > 85 cm in 
women 
2. Dyslipidaemia: serum triglycerides ≥ 150 mg/dl and/or HDL-C < 35 mg/dl in men and 
< 39 mg/dl in women 
3. Urinary albumin excretion rate ≥ 20 µg/min or albumin: creatinine ratio ≥ 30 mg/g 
4. Hypertension: Blood pressure ≥ 140/90 mmHg 
Table 1. WHO definition of the metabolic syndrome 1999 
The potential disadvantage of the WHO criteria is that special testing of glucose status, 
beyond routine clinical assessment, is necessary to diagnose the metabolic syndrome, for 
example: oral glucose tolerance test (OGTT) and insulin resistance measurement by 
hyperinsulinemic euglycemic clamp. Since insulin clamp evaluation was impractical, most 
epidemiological studies used hyperinsulinemia as a surrogate for insulin resistance[24], [3]. 
Another weak point was related to the non-reliable measurement of obesity by the BMI, 
especially in the elderly, due to the changes in height with advancing age compared to 
younger adults[25]. In addition, for any given BMI tertile, subjects in the top waist tertile 
had a worse risk factor profile than individuals with the same BMI but with lower waist 
circumference measures, meaning that the BMI and waist circumference did not predict the 
risk of metabolic disturbances equally[11]. The greater truncal adipose tissue was 
distinguished as the real risk factor for the metabolic syndrome [25]. Moreover, the 
frequency of microalbuminuria in non-diabetic individuals is very low and, therefore, this 
criterion was relevant only in the presence of diabetes[11].  
3.1.2 EGIR definition 
In 1999, the European Group for the Study of Insulin Resistance (EGIR) proposed an 
alternative definition[26], which was called the insulin resistance syndrome. While the 
WHO definition required an evaluation of insulin resistance under euglycemic 
hyperinsulinemic conditions and was applied alike to diabetic and non-diabetic subjects, the 
EGIR definition excluded the diabetic population and relied on fasting insulin as a surrogate 
marker of insulin resistance. The EGIR definition retained insulin resistance, as an essential 
component and major etiological determinant of the metabolic syndrome. However, waist 
circumference was used as surrogate for obesity measured by the BMI; this represented a 
major deviation in the conceptual development of the metabolic syndrome. In addition, the 
impaired glucose tolerance was not necessary for the recognition of the metabolic syndrome 
(Table 2).  
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EGIR definition of the metabolic syndrome1999[27]  
Hyperinsulinaemia defined as fasting insulin concentration above the upper quartile for the 
non-diabetic subjects* (age and sexes combined) in addition to two or more of the following 
components: 
1.  Central obesity: waist circumference ≥ 94 cm in men or ≥ 80 cm in women 
2. Dyslipidemia: serum triglycerides (TG) >180 mg/dl and/or HDL-C < 40 mg/dl and/or 
drug treatment for dyslipidemia 
3. Hypertension: systolic blood pressure (SBP) ≥ 140 mmHg or diastolic blood pressure 
(DBP) ≥ 90 mmHg and/or drug treatment for hypertension 
4. Fasting plasma glucose ≥ 110 mg/dL, 
* The EGIR insulin resistance syndrome was defined only for non-diabetic subjects. 
Table 2. EGIR definition of the metabolic syndrome1999 
3.1.3 NCEP-ATPIII definitions 
Two years later, the National Education Program’s Adult Treatment Panel III (NCEP-
ATPIII) formulated another definition, designed to have clinical utility. The ATPIII did not 
find enough evidence to recommend routine measurement of insulin sensitivity or the 2-
hour post-challenge glucose intolerance, but included simply a fasting glucose testing[28]. 
Additionally, the cut-off points for each component of the cluster and the way of combining 
them to define the metabolic syndrome differed from the two previous definitions[28]. The 
ATPIII definition is based on a simple set of common clinical measures and diagnostic 
criteria, including waist circumference to identify central obesity, raised triglycerides (TG), 
reduced HDL-C, elevated blood pressure (BP) and raised fasting plasma glucose level. The 
metabolic syndrome diagnosis was established, when 3 out of 5 listed characteristics were 
present (Table 3). The ATPIII criteria were widely used in both clinical practice and 
epidemiological studies. This definition had the advantage of excluding the specific measure 
of insulin sensitivity, and treated all components with equal importance by avoiding the 
emphasis on a single cause [29].  
 
NCEP-ATIII definition of the metabolic syndrome 2001[30]  
Any 3 of 5 following criteria constituted the diagnosis of metabolic syndrome 
1. Central obesity: waist circumference ≥ 102 cm in men or ≥ 88 cm in women 
2. Hypertriglyceridamia: serum TG ≥ 150 mg/dl  
3. Low HDL-C < 40 mg/dl in men and < 50mg/dl in women  
4. Hypertension: SBP ≥ 130 mmHg or DBP ≥ 85 mmHg  
5. Fasting plasma glucose ≥ 110 mg/dL  
Table 3. NCEP-ATIII definition of the metabolic syndrome 2001 
Subsequently, various modifications of the ATPIII definition were developed later by the 
American Heart Association/National Heart, Lung, Blood Institute (AHA/NHLBI) 
including adjustment of waist circumference to lower thresholds particularly in ethnic 
groups, for instance, the Asian American, who are more susceptible to insulin resistance. In 
addition, TG, HDL-C levels, and BP were counted as abnormal when a person was taking 
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drug treatment for these factors. The threshold for elevated fasting plasma glucose was 
reduced from ≥ 110 mg/dL to ≥ 100 mg/dL, in accordance with the American Diabetes 
Association’s guidelines [29] (Table 4). 
 
Revised ATPIII definition of the metabolic syndrome 2005[29]
Any 3 of 5 criteria listed below constitute the diagnosis of metabolic syndrome 
1. Elevated waist circumference ≥102 cm in men or ≥ 88 cm in women
2. Elevated TG ≥ 150 mg/dl and/or drug treatment for elevated TG*
3. Reduced HDL-C < 40 mg/dl in men and < 50 mg/dl in women and/or drug treatment 
for reduced HDL-C
4. Elevated BP ≥ 130 mmHg systolic BP or ≥ 85 mmHg diastolic BP or drug treatment for 
hypertension 
5. Elevated fasting plasma glucose ≥ 100 mg/dL and/or drug treatment for elevated 
glucose 
*Fibrates and nicotinic acid are the most commonly used drugs for elevated TG and 
reduced HDL-C. Patients taking 1 of these drugs were presumed to have high TG and low 
HDL 
Table 4. Revised ATPIII definition of the metabolic syndrome 2005 
3.1.4 IDF definition 
In parallel, a consensus group, comprising members of the International Diabetes Federation 
(IDF) and representatives from organizations which contributed to the previous definitions, 
was formed in 2005 to establish a unified definition for the metabolic syndrome that would 
be suitable for use in both epidemiological and clinical practice. A major issue for the IDF 
consensus was that central (abdominal) obesity was a prerequisite risk factor for the 
diagnosis of the syndrome. The IDF provided, for the first time, different obesity cut-off 
points for different ethnic groups (Table 5 & 6). Waist circumference was a well accepted 
proxy measurement for abdominal obesity and served as the first screening test for the 
metabolic syndrome. The added advantage is that insulin resistance which is difficult to 
measure in routine clinical practice was not an essential requirement[31].  
 
The IDF definition of the metabolic syndrome 2005[31]
Central obesity (defined as waist circumference with ethnicity specific values) plus any 2 of 
the following 4 factors:
1. Raised serum TG ≥ 150 mg/dl or specific treatment for this lipid abnormality 
2. Reduced HDL-C < 40 mg/dl in men and < 50 mg/dl in women and/or specific 
treatment for this lipid abnormality
3. Elevated BP ≥ 130 mmHg systolic BP or ≥ 85 mmHg diastolic BP and/or treatment of 
previously diagnosed hypertension
4. Elevated fasting plasma glucose ≥ 100 mg/dL or previously diagnosed type 2 diabetes. 
If Fasting plasma glucose was above 100 mg/dL, oral glucose tolerance test (OGTT) was 
strongly recommended but was not necessary to define the presence of the metabolic 
syndrome. 
Table 5. The IDF definition of the metabolic syndrome 2005 
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The underlying principle behind the ethnic-specific thresholds was that for a given waist 
circumference, Asians, Blacks, Caucasians showed different levels of intra-abdominal 
adiposity, putting the subjects at different risk levels of cardiovascular disease and 
diabetes[32].  
 
Country/Ethnic group  Waist circumference 
Europids 
In the USA, the ATP III values 
(102 cm male; 88 cm female) 
are likely to continue to be used for 
clinical purposes 
Male  ≥ 94 cm 
Female  ≥ 80 cm 
South Asians 
Based on a Chinese, Malay and 
Asian-Indian population 
Male  ≥ 90 cm 
Female ≥ 80 cm 
Chinese 
Male  ≥ 90 cm 
Female  ≥ 80 cm 
Japanese 
Male  ≥ 90 cm 
Female ≥ 80 cm 
Ethnic South and Central 
Americans 
Use South Asian recommendations until more 
specific data are available 
Sub-Saharan Africans 
Use European data until more specific data are 
available 
Eastern Mediterranean and 
Middle East (Arab) populations 
Use European data until more specific data are 
available 
Table 6. Ethnic specific values for waist circumference 
3.1.5 Last Joint Interim Statement  
In 2009, a Joint Interim Statement (JIS) of the IDF Task force on Epidemiology and 
prevention (National Heart, Lung, and Blood Institute; American Heart Association; World 
Heart Federation; International Atherosclerosis Society; and International Association for 
the Study of obesity) was published, in an attempt to harmonize the definition. The new 
definition is also known as Revised IDF 2005. Unlike the first IDF definition, the abdominal 
obesity should not be an obligatory criterion, though the waist circumference was agreed to 
be a useful preliminary screening tool. The remaining 4 diagnostic criteria were essentially 
identical to those provided by the R-ATPIII and IDF. The presence of 3 components out of 5 
establishes the diagnosis of metabolic syndrome (Table 7).  
This new definition recognizes that the risk associated with a particular waist measurement 
varies in different populations and ethnic groups. The WHO identified 2 levels of abdominal 
obesity in European population depending on risk for metabolic complications[34]. An 
increased risk occurs at waist circumferences of ≥ 94 cm in men or ≥ 80 cm in women, but 
risk is substantially higher at ≥ 102 cm in men or ≥ 88 cm in women. Until more data from 
research work become available, it was suggested to use national or regional cut-off points 
for waist circumference. 
To sum up, the abundance of widely varying data, comparing the prevalence of metabolic 
syndrome by using different criteria across different populations reinforced the need for a 
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standardized definition internationally. Now after the release of the JIS, the current question 
is whether this new definition is the last word or whether the scientific community needs 
further reconciliation.  
 
Joint Interim Statement definition of the metabolic syndrome 2009 [33] 
Any 3 of 5 criteria listed below constitute the diagnosis of metabolic syndrome 
1. Elevated waist circumference according to population- and country-specific definitions 
(either the IDF or AHA/NHLBI cut points for people of European origin) 
2. Elevated TG ≥ 150 mg/dl or drug treatment for elevated TG 
3. Reduced HDL-C < 40 mg/dl in men and < 50 mg/dl in women or drug treatment for 
reduced HDL-C 
4. Elevated BP ≥ 130 mmHg systolic BP or ≥ 85 mmHg diastolic BP and/or drug treatment 
for hypertension 
5. Elevated fasting plasma glucose ≥ 100 mg/dL or drug treatment for elevated glucose 
Table 7. Last Joint Interim Statement definition of the metabolic syndrome 2009 
3.2 Ambiguous pathophysiologic mechanism 
The pathogenesis of the metabolic syndrome is currently a subject of crucial discussion. The 
criteria of metabolic syndrome are interrelated, but the pathophysiology of their relation is 
not yet fully understood. The long-standing debate about how to define this syndrome led 
to the appearance of two distinct schools of thought: the insulin resistance-based and the 
ectopic fat deposition-based hypothesis. So far, both suggested mechanisms remain 
equivocal and debated. 
The basic scientists and endocrinologists support the point of view that the insulin 
resistance and compensatory hyperinsulinemia are squarely responsible for the metabolic 
syndrome [13], [21], [35]. According to this group, obesity is thought to exacerbate insulin 
resistance and thus increase the likelihood of an associated adverse clinical condition. 
However, the obesity is not considered as a fundamental component of the syndrome, as the 
clustering of risk factors can occur in insulin resistant individuals of normal weight[36], [37]. 
The primary goal of this pathophysiological approach is to alert physicians to the idea that 
patients with insulin resistance are not only at risk for cardiovascular disease, but also to 
other multiple adverse clinical conditions such as polycystic ovarian syndrome, 
nonalcoholic fatty liver disease, breast cancer, sleep apnoea. Cardiovascular disease is just 
one of these important conditions. This group of researchers do not seek strict clinical 
definition for the metabolic syndrome[38].  
In opposition, the other group consists of cardiologists and clinical epidemiologists. This 
group support the term “metabolic syndrome” and seek to assemble a set of related 
metabolic risk factors for cardiovascular prevention perspectives. In line with this 
viewpoint, obesity is considered as a core component of the metabolic syndrome rather than 
a modulator of the effects of insulin resistance[39]. The primary clinical goal of this school of 
thought is to suggest an operational tool to be used for long-term risk stratification of 
atherosclerosis patients [40], [29]. This group supports the idea that the abdominal obesity is 
the predominant driving force behind the metabolic syndrome and is a particularly 
detrimental factor in persons who have concomitant metabolic susceptibility from other 
causes.  
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Chronologically, the pathophysiological “Insulin Resistance Syndrome” transmuted into 
clinical “Metabolic Syndrome” in the 1990s[41]. This shift happened to help the scientists to 
translate science into practice in an area of major medical and public health concern. As 
insulin resistance was difficult to be measured by the glucose clamp technique, at the 
population level, fasting plasma insulin levels was used as a proxy to prompt the research 
for cheap, easy surrogates of insulin resistance[41]. However, this introduced a confusion 
because of the partial difference in the physiology of hyperinsulinemia and insulin 
resistance[42], as well as a lack of measurement standardization across studies[41].  
Thereafter, anthropometric measures were suggested to replace insulin resistance in new 
definitions of the metabolic syndrome. The NCEP-ATPIII and particularly the IDF, took the 
position that obesity (especially abdominal obesity) is a dominant factor behind the 
multiplication of risk factors. According to the NCEP, the onset of obesity elicits a clustering 
of risk factors in persons who are metabolically susceptible[40].  
In sum, the metabolic susceptibility has many contributing factors, including genetic forms 
of insulin resistance, increased abdominal fat, ethnic and racial influences, physical 
inactivity, advancing age, endocrine dysfunction, and genetic diversity[43]. However, the 
relevance of this application has not yet exclusively been established by the research[41].  
3.3 Uncertain clinical utility  
Although the suggested definitions provided some uniformity to researchers, a considerable 
confusion about the precise clinical utility of the “metabolic syndrome” exists and remains 
controversial.  
The major polemic emerged in 2005 when a joint committee of the American Diabetes 
Association (ADA) and from the European Association for the Study of Diabetes (EASD) 
published a critical appraisal of the metabolic syndrome concept, and of its diagnostic utility 
in clinical practice[22]. This group of researchers opposed extending the concept of the 
metabolic syndrome to clinical practice and objected to characterize the metabolic syndrome 
as a risk factor for heart disease or diabetes[22], [44]. The claim was that the primary clinical 
emphasis should remain on treating the individual risk factors and that aggregating them 
into a syndrome has little clinical utility. Moreover, creating a diagnostic category of the 
metabolic syndrome was criticized by Reaven himself who was a pioneer in systemizing the 
concept of a risk factor syndrome. Reaven believed that this effort had little clinical or 
pedagogic utility and if necessary the WHO approach was the most rational one[44]. In this 
line, the WHO Expert Consultation, who edited the first definition 10 years earlier, released 
in 2009 a Position Statement, pertaining to evaluate the relevance and the clinical utility of 
the metabolic syndrome concept[38]. The statement critically concluded that though the 
metabolic syndrome may be considered useful as an educational concept, it has limited 
practical utility as a diagnostic or management tool. 
The counter arguments, represented principally by the IDF and AHA, advocated that the 
diagnosis of the metabolic syndrome helps physicians to discover persons at increased lifetime 
risk for cardiovascular disease [45], [46]. They believe that the metabolic syndrome is a simple 
useful tool to call attention to patients who are at high lifetime risk for both atherosclerotic 
cardiovascular disease and diabetes; such persons deserve increased attention in clinical 
management and monitoring[23], [26], [29], [22],[44]. Grundy was the scientist who most 
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thoroughly advocated the clinical utility of the metabolic syndrome, by linking the importance 
of clinical metabolic syndrome recognition to an “iceberg phenomenon”[43]. He explained that 
identifying the metabolic syndrome provides a simple means of recognising the risk, 
submerged in a tangle of metabolic derangement[43]. According to Grundy, seeing the tip of 
the iceberg can be lifesaving because most of the danger lies below. The same is true in case of 
finding aggregated metabolic signs such as high TG, low HDL-C, impaired fasting plasma 
glucose, and mildly elevated BP in a patient with an increased waist circumference [43].  
Although the metabolic syndrome seemed to provide little advantage over the available risks 
scores (Framingham or European SCORE)[47], [22], several clinicians believe that the clinical 
diagnosis is useful because it determines the therapeutic strategy in patients at higher risk[43]. 
Moreover, the application of the available cardiovascular disease risk scores is still 
cumbersome and not routinely used in clinical practice. The metabolic syndrome may thus 
represent a simple convenient alternative tool to identify individuals at increased risk of 
atherosclerotic cardiovascular disease or type 2 diabetes mellitus[48], [46]. Beyond risk 
assessment, the presence of the metabolic syndrome can alert clinicians to the likelihood of 
related pathological conditions, e.g. obstructive sleep apnoea, fatty liver, cholesterol gallstones, 
and polycystic ovarian disease[45]. In addition, it helps to recognize that patients with a 
clustering of measured risk factors usually have several hidden metabolic risk factors, e.g, a 
prothrombotic state, a proinflammatory state, and multiple lipoprotein abnormalities[29], [46].  
3.4 Debated therapeutic strategies 
Globally, there are two viewpoints about the best therapeutic strategy for patients with the 
metabolic syndrome. One conventional approach holds that each of the metabolic risk factors 
should be singled out and treated separately. However, the concern about this prescription is 
that it may lead to an aggressive use of medications at the expense of lifestyle therapies, 
particularly, weight reduction and increased exercise[43]. Alternatively, the other view 
emphasizes the global approach that aims to implement lifestyle therapies to reduce all risk 
factors simultaneously. It targets multiple risk factors together by striking at the underlying 
causes. Treating the underlying causes does not rule out the management of individual risk 
factors, but it may reinforce the control of multiple risk factors[43]. In practice, there is a 
tendency to switch from a vertical approach (by speciality) to a multidisciplinary horizontal 
approach, which enables early detection of the combination of risk factors, sometimes without 
obvious illness, as measure of effective prevention. So far, there is no proof that the lifestyle 
modification interventions targeting the metabolic syndrome are superior to those targeting 
the individual components[22], [48]. Recently, a new study published in 2010 analyzed data 
from the INTERHEART study, a case-control study of incident acute myocardial infarction 
that involved 12 297 cases and 14 606 controls from 52 countries. The results suggested that 
patients with metabolic syndrome are not at higher risk of future myocardial infarction than 
those with diabetes or hypertension alone[49]. The results strongly suggested that treating the 
individual risk factors is rather better than focusing on the metabolic syndrome, supporting 
therefore, the individual risk-factor approach. 
3.5 Predictability of the metabolic syndrome to cardiovascular risk  
One of the most important criticisms addressed to the concept of the metabolic syndrome 
was its efficiency to properly evaluate the global cardiovascular disease risk in clinical 
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practice. The plethora of epidemiological, metabolic and clinical studies, published over the 
last 2 decades, have demonstrated that the different definitions of the metabolic syndrome 
were able to identify subgroups of patients at greater risk of type 2 diabetes[50] and at 
increased relative risk of coronary heart disease[51], [52]. Nevertheless, none of these 
definitions can properly assess global cardiovascular disease risk [32].  
Many prospective studies documented the relation of metabolic syndrome to cardiovascular 
risk, particularly to cardiovascular morbidity, mortality as well as all-cause mortality. In the 
Kuopio Ischemic Heart Disease Risk Factor Study, a population-based, prospective cohort 
study of 1209 Finnish men aged 42 to 60 years, the 10-year cardiovascular disease risk was 
increased 2.1- and 2.5-fold with the ATP III and WHO definitions, respectively[3]. The same 
study found that the risk of death from cardiovascular disease was increased by 2.6–3 times, 
and the risk of all-cause mortality was increased 1.9–2.1 times with the presence of 
metabolic syndrome. The DECODE project, based on 11 prospective European cohort 
studies, comprising 6156 men and 5356 women, aged from 30 to 89 years reported that the 
overall hazard ratios for all-cause and cardiovascular mortality in non-diabetic persons with 
the metabolic syndrome were 1.44 and 2.26 in men and 1.38 and 2.78 in women, 
respectively[12]. In the WOSCOPS (West of Scotland Coronary Prevention) Study, a 
modified NCEP definition predicted CHD events, in the multivariate model incorporating 
conventional risk factors (hazard ratio=1.30). Men with 4 or 5 features of the metabolic 
syndrome had a 3.7-fold increase in risk for CHD and a 24.5-fold increase for diabetes 
compared with men without the syndrome [53]. In Botnia study, carried out on 4483 
subjects, aged 35-70 years, followed for 7 years in Finland and Sweden, the risk for coronary 
heart disease and stroke was increased 3-fold in subjects with the WHO defined metabolic 
syndrome. Cardiovascular mortality was also markedly increased in subjects with the 
syndrome compared to those without it (12.0% vs. 2.2%, P < 0.001)[2]. 
In sum, the use of different definitions of the metabolic syndrome led to inconsistent results 
on its association with the risk of cardiovascular disease [51]. Systematic research reviews 
showed that the cardiovascular risk, conferred by the different definitions, varied between 
populations; in most studies, it was lower with the IDF definition as compared to other 
alternatives[54], [51]. In addition, two recent meta-analyses of longitudinal studies, showed 
that the relative risk of cardiovascular disease associated with the metabolic syndrome was 
higher in women compared to men[52], and higher in studies that used the WHO definition 
compared to studies that used the NCEP-ATP III definition[51]. 
3.6 Predictability of the metabolic syndrome to type 2 diabetes  
The most important clinical dimension of the metabolic syndrome is its association with the 
risk of development of type 2 diabetes. Several prospective studies indicated that the 
metabolic syndrome predicts type 2 diabetes[24], [55], [56]. People with the syndrome were 
over 4 times as likely to develop type 2 diabetes compared with subjects who did not have 
it[1], although without excluding the diabetic subjects, this might not be surprising, since 
impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) are components of the 
WHO definition[16]. In addition, neither the ATP III nor the IDF criteria excluded 
hyperglycaemia as 1 of the 5 criteria for the diagnosis of the metabolic syndrome. By these 
criteria, most patients with type 2 diabetes mellitus have the metabolic syndrome. In the San 
Antonio Heart Study, the NCEP definition of the metabolic syndrome predicted diabetes 
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better than the WHO definition, independently of other factors. It was suggested therefore 
to lower the fasting glucose cut-off points to improve the diabetes prediction [55].  
Despite the above data, there is an ongoing controversy as to whether the metabolic 
syndrome is associated with increased cardiovascular and diabetes risk or is simply a sum 
of the risk of the associated components: glucose tolerance, elevated blood pressure, 
dyslipidemia, and abdominal obesity[9]. According to a recent research review, aimed to 
examine the ability of the metabolic syndrome to predict vascular events and incident 
diabetes, the number of existing studies appeared limited to draw definite conclusions[54] 
and the metabolic syndrome predicts diabetes much more efficiently in non-diabetic 
individuals[57]. 
4. Evolution toward a new global “cardiometabolic risk” concept 
The traditional risk assessment algorithms (Framingham, PROCAM or European SCORE, 
etc.) take into account classical risk factors such as age, sex, family history, blood pressure, 
smoking, cholesterol (both LDL and HDL), and diabetes. However, these risk assessment 
tools do not capture the risk of abdominal obesity and the related abnormalities of the 
metabolic syndrome. This is especially important with the recent sweeping epidemic of 
abdominal obesity, where many individuals are at increased risk of cardiovascular disease 
because of the presence of a constellation of metabolic abnormalities. It has been suggested 
that the cardiovascular disease risk of abdominal obesity and/or metabolic syndrome may 
be independent from or go beyond the risk predicted by traditional risk factors [32]. 
Moreover, the Framingham risk score does not assess properly lifetime risk particularly 
among young adults with abdominal obesity and metabolic syndrome who may not be 
considered at elevated risk of cardiovascular disease because of their young age[45]. 
Therefore, the existing cardiovascular disease risk assessment tools proved cumbersome in 
clinical practice and were not sufficient to adequately capture the additional risk related to 
the metabolic syndrome, such as the abdominal obesity, insulin resistance and related 
complications [32].  
On the other hand, the metabolic syndrome as a clinical entity could not improve prediction 
of risk of cardiovascular disease [47], [22], because it did not incorporate important 
traditional risk factors, such as smoking, age and gender[45]. The current recommendations 
stress the need to focus on the assessment of the total burden of risk, the so-called global risk 
profile, rather than on individual or particular risk factor. This is because, the absolute risk 
of an acute coronary event depends on the totality of interacting risk determinants; some 
associated with adult lifestyle, others operating from early childhood[58]. 
On the whole, the presence of metabolic syndrome alone cannot predict global 
cardiovascular disease risk, nor do the available risk scores. Meanwhile, better risk 
assessment algorithms are needed to quantify diabetes and cardiovascular disease risk on a 
global scale[59]. This unremitting debate, as to whether the metabolic syndrome increases 
cardiovascular disease risk beyond the risk posed by traditional cardiovascular disease risk 
factors, has spurred the creation of a new concept named the global “cardiometabolic risk 
(CMR)”. In order to move the field forward, a multidisciplinary International Chair on CMR 
was created, at the end of 2005, to provide a platform to discuss the concepts of abdominal 
obesity, metabolic syndrome, and global cardiovascular disease risk[32]. 
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Global CMR is defined as the risk of cardiovascular disease resulting from the presence of 
traditional risk factors along with features of the metabolic syndrome [32], [59]. Under this 
model, CMR encompasses the overall cardiovascular disease risk, resulting from traditional 
risk factors (age, sex, smoking, hypertension, LDL cholesterol, HDL cholesterol, diabetes) 
and from the additional risks of intra-abdominal obesity or related features of the metabolic 
syndrome [32]. Under this working model, the metabolic syndrome is one of the potentially 
modifiable cardiovascular disease risk factors, besides smoking (Figure 1). It has been 
suggested that the cardiovascular risk of abdominal obesity/metabolic syndrome may be 
independent of or go beyond the risk predicted by traditional risk factors.  
 
Fig. 1. The “building blocks” of global cardiometabolic risk, with adaptation from Desprès et 
al[32]. 
5. Epidemiology of metabolic syndrome 
The metabolic syndrome is a cluster of cardiovascular risk factors associated with an 
increased risk of type 2 diabetes mellitus and cardiovascular morbidity and mortality[3]. 
This section aims to shed light on the current state-of-art with regards to the prevalence of 
the metabolic syndrome worldwide and its key determinants. Understanding the 
epidemiology of the metabolic syndrome, as regards the variation of its frequencies and its 
potential determinants, are essential pre-requisites to addressing public health needs. 
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5.1 Prevalence of metabolic syndrome  
The multiplicity of prevalence data suggest that the metabolic syndrome is common 
worldwide, especially among older people and in certain ethnic populations[15]. The 
syndrome will undoubtedly become even more common over time, in parallel with the 
exploding epidemic of obesity and type 2 diabetes[60]. In addition, the worldwide increase 
in the prevalence of metabolic syndrome among children and adolescents[61], constitutes a 
greater public health concern, as emerging evidence has suggested that children with the 
metabolic syndrome increase their risk of developing adverse cardiovascular events later in 
life[62].  
In this setting, the present section describes and compares the metabolic syndrome prevalence 
rates reported in different studies, carried out during the current decade, in various countries 
all over the world. A thorough literature search for publications, documenting the prevalence 
of the metabolic syndrome according to the existing definitions, was conducted with an 
emphasis on international prevalence comparison. The reported worldwide prevalence rates 
of the metabolic syndrome are depicted in Table 8 (A-D).  
Globally, the prevalence of the metabolic syndrome was different across the countries in 
terms of gender, age groups and ethnicity, regardless of the definition used. In US 
population, the IDF definition led to a higher prevalence estimate (39%) than that based on 
the R-ATPIII criteria (34.5%)[63]. A spectacular increase in the prevalence was recorded 
among the same population, from 24% in 1988[63] to 34.5% in 2002[64], by using the NCEP-
ATPIII definition. This raise was attributed to the increase in the prevalence of obesity 
between 1988 and 2000, as well as the aging of the population[65]. In European studies, the 
prevalence of the metabolic syndrome varied considerably between 18% in Italy[66] and 
38% in Turkey[67]. The metabolic syndrome was also frequent in Middle Eastern 
countries[68] and India[69], although the lowest prevalence rates were recorded in 
Australia[70], and china[71]. Generally, the IDF criteria gave a higher prevalence rate as 
compared to the NCEP-ATPIII[60]. This was undoubtedly attributable to the lower waist 
circumference threshold to define the abdominal obesity criterion. The WHO criteria 
variably induced a higher prevalence rate when compared to the NCEP-ATPIII definition 
[60]. 
Irrespective of the criteria, studies were inconsistent regarding the gender-specific metabolic 
syndrome prevalence. While the metabolic syndrome was higher among men than women 
in France[72], [73], Germany[50], Ireland[74], Singapore[75], it was higher in Omani[68], 
Chinese[71] and Indian women[69]. In addition, accumulating evidence demonstrated that 
the prevalence of the metabolic syndrome was highly age-dependent, so as its individual 
components[15]. The prevalence increases with age through the sixth decade of life among 
men and seventh decade among women [76]. Race/ethnicity influenced also the prevalence 
of the metabolic syndrome. Some ethnic groups have a higher predisposition to central 
obesity than others: for example, the prevalence of central obesity is higher among South 
Asians than in Europeans. Asian populations have more metabolic abnormalities with the 
same obesity than do the Caucasians[71]. Thus, a modification of the waist circumference 
cut-off values of the NCEP-ATPIII definition has been proposed for Asian populations. By 
applying the European definition of waist circumference, the prevalence of metabolic 
syndrome was generally lower among Asian populations than among European 
populations, however, when modified Asian waist circumference criteria were used, the 
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prevalence of metabolic syndrome increased and became similar (Korean population)[77] to 
or even higher (urban Indians)[69] than European populations. In USA, NCEP ATPIII-
defined metabolic syndrome is more prevalent in Mexican Americans (31.9%) than in 
Caucasian (23.8%) and African American (21.6%)[7]. Ford et al reported that the metabolic 
syndrome was more common in Black and Hispanic women than in both counterpart men, 
which contrasted with the similar gender prevalence for Whites [7]. 
 
Country, 
year of 
publication 
Acronym, 
setting and 
period of data 
collection 
Study design Age group and 
subjects 
number 
Definition subject’s 
characteristics 
Age-
adjusted 
Prevalence 
of 
metabolic 
syndrome 
USA, 
2002[7] 
 
Third National 
Health and 
Nutrition 
Examination 
Survey 
(NHANESIII), 
1988-1994 
Cross-sectional 
population-
based sample 
≥20years 
(8814 subjects) 
NCEP ATPIII White  23.8%* 
Mexican 
American 
31.9%* 
African 
American 
21.6%* 
Other  20.3%* 
USA, 
2004[84] 
 
Dearborn, 
Michigan, 2004
Cross-sectional,
random sample
20-75years,  
(542 subjects) 
NCEP ATPIII
 
Arab 
Americans 
population 
23% * 
 
WHO 28% * 
USA, 
2003[64] 
 
Third National 
Health and 
Nutrition 
Examination 
Survey 
(NHANESIII), 
1988-1994 
Cross-sectional,
representative 
sample 
≥ 20 years,  
(8608 
participants) 
NCEP ATPIII Total 23.9%* 
Men 24.2% * 
Women 23.5%* 
WHO Total 25.1%* 
Men 27.9%* 
Women 22.6%* 
USA, 
2005[63] 
 
 
National 
Health and 
Nutrition 
Examination 
Survey 
(NHANES), 
1999-2002 
Cross-sectional 
population-
based sample 
≥ 20years 
(3601 subjects) 
NCEP ATPIII Total 34.5% 
Men 33.7% 
Women 35.4% 
IDF Total 39% 
Men 39.9%  
Women 38.1% 
*Non age-adjusted prevalence rate 
A Prevalence of the metabolic syndrome in USA 
Table 8. Prevalence of the metabolic syndrome in different countries.  
In fact, the cross-sectional and longitudinal epidemiological studies provided markedly 
different prevalence and incidence rates of the metabolic syndrome, because of the lack of 
internationally agreed-upon criteria to define the syndrome. The NHANES III surveys 
carried out in USA, aimed at comparing the prevalence of the metabolic syndrome 
according to the WHO and NCEP-ATPIII definitions, demonstrated a substantial 
discordance for gender and ethnicity[64]. The IDF definition, led generally to higher 
estimates of the prevalence, in all ethnic groups, especially among Mexican American men 
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[63]. An elevated IDF prevalence of the metabolic syndrome was similarly observed in other 
international studies[70], [78], [79], [66], [80], [67], [81]. In 8 European cohorts (DECODE 
Study), the metabolic syndrome prevalence rate defined according to the WHO, NCEP-
ATPIII and EGIR varied widely among countries; the WHO definition showed particularly a 
wide gender-specific difference[82]. In Bruneck Italian Study, the prevalence of metabolic 
syndrome was significantly higher and almost doubled with the WHO criteria as compared 
to those of the NCEP (34.1% vs 17.8% respectively)[46]. 
Apart from definitions diversity, the wide variation of published data made direct 
international comparisons exceedingly difficult, because of important methodological 
differences with respect to the characteristics of target population, the study design, the 
sample selection, and the year of conduct.  
In sum, the emerging prevalence data from population-based studies suggest that the 
metabolic syndrome is a quite common cardiometabolic disorder worldwide with a wide 
gender discrepancy. A very consistent finding was that the prevalence of the metabolic 
syndrome increased dramatically with age and varied considerably across ethnic groups. 
Racial/ethnic waist circumference component heterogeneity gave rise to substantial 
racial/ethnic variation in the prevalence of the metabolic syndrome itself. The use of 
different definitions in diverse populations resulted in wide ranging prevalence rates, thus 
highlighting the urgent need for a unified definition[83]. Moreover, only a few international 
studies reported age-adjusted prevalence rates, to enable meaningful comparison. 
 
Australia, 
2005[70] 
Adelaide, 
south 
Australia 
study,  
Random 
household 
sample 
≥ 18 years,  
(4060 
subjects) 
NCEP ATPIII Total 15% 
Men 15.7% 
Women 14.4% 
IDF Total 22.8% 
Men 26.4% 
Women 19.4% 
B Prevalence of the metabolic syndrome in Australia 
Table 8. Prevalence of the metabolic syndrome in different countries. 
 
Country, 
year of 
publication 
Acronym, 
setting and 
period of 
data 
collection 
Study design Age group 
and subjects 
number 
Definition Subject’s 
characteristics 
Age-
adjusted 
Prevalence 
rate 
Europe, 
2005[82] 
The 
DECODE 
Study Group, 
1991, except 
in Spain 
(1996-1997) 
Seven cross-
sectional 
European 
population-
based studies 
30-77years, 
(9140 
subjects), 
Non-diabetic 
Europeans 
WHO Men 26.9% 
Women 19.5% 
EGIR Men 17.9% 
Women 16.5%  
NCEP ATPIII
 
Men 22.7%  
Women 23.1% 
Germany, 
2008[50] 
The 
European 
Prospective 
Multi-centre, 
prospective 
cohort study 
35-65years,  
(2796 
subjects) 
Revised 
NCEP ATPIII
 
Total 22.5% * 
Men 29.1%*  
Women 18.5%* 
www.intechopen.com
 
Cardiovascular Risk Factors 
 
176 
Country, 
year of 
publication 
Acronym, 
setting and 
period of 
data 
collection 
Study design Age group 
and subjects 
number 
Definition Subject’s 
characteristics 
Age-
adjusted 
Prevalence 
rate 
Investigation 
into Cancer 
and 
Nutrition-
Potsdam 
Study (EPIC) 
Potsdam, 
1994-1998  
IDF Total 28.3% * 
Men 33.2%*  
Women 25.2% * 
France, 
2006[72] 
D.E.S.I.R 
Study, 
centre-
western 
France, 1994-
1996 
Volunteered for 
health check-up 
5446 
subjects, 30-
64 years 
Revised 
NCEP ATPIII
Men 15% 
Women 10.1% 
France, 
2003[73] 
Centre IPC 
(Investigatio
n Préventives 
et Cliniques), 
Paris, 1999-
2002 
Volunteered for 
health check-up 
62000 
subjects, 
(mean age 
53.2+/-
9.1years) 
Revised 
NCEP ATPIII
Men 11.8%* 
Women 7.6%* 
Norway, 
2007[78] 
Nord-
Trondelag 
Heart 
Study(HUNT
2), 1995-1997
Cross-sectional 
population-
based sample 
20-89 years, 
(10206 
subjects 
Revised 
NCEP ATPIII
 25.9%* 
IDF 29.6%* 
Finland, 
2007[79]  
The 
Cardiovascul
ar risk in 
Yong Finns 
Study, 1986-
2001 
Population-
based follow-up 
study 
2182 
subjects, 24-
39 years 
Revised 
NCEP ATPIII
Total  13% 
EGIR 9.8% 
IDF 14.3% 
Ireland, 
2003[74] 
 Primary care 
setting in the 
South of 
Ireland. 
Random sample 
of attended 
subjects for 
screening from 
17 general 
practice lists  
50–69 years,
(1,018 
subjects) 
WHO Total 21%* 
Men 24.6%* 
Women 17.8%* 
NCEP-ATPIII Total 20.7%* 
Men 21.8%* 
Women 21.5%* 
Italy, 
2003[46] 
Bruneck 
Study, 1990 
Prospective 
population-
based survey 
40–79 years,
888 subjects
WHO   34.1%* 
NCEP ATPIII 17.8%* 
Italy, 
2007[66] 
FIBAR study, Sample of 
individuals 
enrolled in a 
2,945 
subjects, 
mean age 
Revised 
NCEP ATPIII
Total  16.6%* 
IDF 29.7%* 
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Country, 
year of 
publication 
Acronym, 
setting and 
period of 
data 
collection 
Study design Age group 
and subjects 
number 
Definition Subject’s 
characteristics 
Age-
adjusted 
Prevalence 
rate 
screening 
program for 
diabetes 
55.2+/-11.5 
years 
Spain, 
2003[85] 
Nutritional 
Survey of the 
Canary 
Islands 
(ENCA), 
1997-1998) 
Population–
based study 
18-74 years, 
578 adults 
NCEP ATPIII Total  24.4%* 
Spain, 2007 Province of 
Albacete 
Cross-sectional, 
Population–
based study 
40-70 years, 
425 subjects
Adapted 
NCEP ATPIII
Total 20.9% 
Greece, 
2007[86] 
Greece cross-sectional, a 
representative 
sample  
adults, 9669 
subjects 
NCEP-ATP-
III 
 23.3% 
Revised 
NCEP ATPIII
 22.6% 
IDF  18.3% 
Portugal, 
2007[80] 
Porto Representative 
random sample, 
Population-
based study 
18-92 
years,1433 
subjects 
WHO  adult residents 26.4% 
NCEP ATPIII 
2001 
24% 
IDF 41.9% 
AHA/NHLBI 
2005 
37.2% 
Portugal, 
2008[87] 
VALSIM 
Study 
Primary health 
care users 
18-96 years, 
16,856 
subjects 
NCEP ATPIII total 27.5% 
Alentejo 
region 
30.99% 
Algrave region 24.42% 
Turkey, 
2007[67] 
Turkish 
Heart Study, 
2003 
Cross-sectional 
population-
based sample 
mean age 
45± 13 years, 
(1568 
subjects) 
WHO General adult 
population 
19%  
    EGIR  20%  
    NCEP ATPIII  38%  
    IDF  42%  
Luxembourg
, 2011[88] 
ORISCAV-
LUX survey, 
Luxembourg, 
2007-2008 
Cross-sectional 
population-
based sample 
18-69 years, 
1432 subjects
R-ATP III General adult 
population 
24.7%* 
    JIS (94/80cm)  28.0%* 
C Prevalence of the metabolic syndrome in European countries 
Table 8. Prevalence of the metabolic syndrome in different countries 
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Country, 
year of 
publication 
Acronym, 
setting and 
period of data 
collection 
Study design Age group 
and subjects 
number 
Definition subject’s 
characteristics 
Age-
adjusted 
Prevalence 
rate  
Oman, 
2003[68] 
Nizwa study, 
2001 
Cross-sectional 
population-
based sample 
≥ 20years,  
(1419 
subjects) 
NCEP ATPIII
 
Total 21%  
Men 19.5%  
Women 23% 
Chile, 
2008[81] 
Talca city 
study, year of 
data collection 
not mentioned
Probabilistic 
sample 
18-74 years, 
(1007 
subjects) 
Revised NCEP 
ATPIII 
 29.5%  
IDF 36.4%  
China, 
2006[71] 
The Chinese 
Multiprovincial 
Study, 1992 
Prospective 
cohort study 
35-64 years, 
(26972 
subjects) 
ATPIII 
according to 
Asian criteria 
of waist 
circumference
Men (≥ 90cm) 14.4% 
Women (≥ 
80cm) 
20% 
IDF according 
to Asian 
criteria of 
waist 
circumference
Men (≥ 90cm) 9.8% 
Women (≥ 
80cm) 
16.6% 
South 
Korea, 
2004[77] 
Mokdong 
Study of 
Diabetes 
Prevalence, 
1997 
Random cluster 
sample  
30-80 years,  
(1804 
subjects) 
ATPIII based 
on Asia-Pacific 
guidelines 
Men (≥ 90cm) 29%* 
Women (≥ 
80cm) 
16.8%* 
ATPIII  Men (≥ 102 
cm) 
16%* 
Women ≥ 
88cm) 
10.7%* 
South 
Korea, 
2006[89] 
Korean 
National 
Health and 
Nutrition 
Examination 
survey, 1998 
Stratified 
multistage 
probability 
sampling 
design 
20-80 years,  
(6824 
subjects) 
IDF (with 
specific waist 
circumference 
cut-off points)
Men (≥ 90cm) 13.5% 
Women (≥ 
85cm) 
15% 
India, 
2004[69] 
Urban Indian 
population 
study 
Population-
based study 
>20 years, 
(1123 
subjects) 
ATPIII Total 24.9% 
Men 18.4% 
Women 30.9% 
Seychelles 
(Indian 
Ocean, 
African 
region), 
2008[90] 
Seychelles 
Heart Study III, 
2004 
Cross-sectional, 
Population-
based study 
25-64 years, 
(1218 
subjects) 
WHO Men 25%* 
Women 24.6%* 
ATPIII Men 24%* 
Women 32.2%* 
IDF Men 25.1%* 
Women 35.4%* 
Singapore, 
2004[75] 
Singapore 
National 
Health Survey, 
1998 
Population-
based study 
18-69 years, 
(4723 
subjects) 
NCEP Men (all races) 13.1% 
Chinese 10.8% 
Malays 17.3% 
Asian Indians 21.7% 
Women (all 
races) 
11% 
Chinese 8.3% 
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Country, 
year of 
publication 
Acronym, 
setting and 
period of data 
collection 
Study design Age group 
and subjects 
number 
Definition subject’s 
characteristics 
Age-
adjusted 
Prevalence 
rate  
Malays 20% 
Asian Indians 19.3% 
NCEP-Asian 
criteria  
(Waist 
circumference
90 cm in men 
and  
80 cm in 
women) 
Men (all races) 20.9% 
Chinese 18.1% 
Malays 24.7% 
Asian Indians 32.4% 
Women (all 
races) 
15.5% 
Chinese 12.5% 
Malays 23.8% 
Asian Indians 25.8% 
D Prevalence of the metabolic syndrome in Asian countries 
Table 8. Prevalence of the metabolic syndrome in different countries 
5.2 Potential determinants of the metabolic syndrome 
At every stage of life, health is determined by complex interactions between a multitude of 
factors that influence a person’s disease or health status. With regards to the metabolic 
syndrome, the determinants which are centrally involved in its multi-factorial causation can 
be categorized as: biological or genetic susceptibility; socio-economic; environmental and 
behavioural factors.  
5.2.1 Biological or genetic susceptibility  
Although twin and family studies showed a high heritability for each of the individual 
components [91], the genetic basis of the metabolic syndrome, as a composite phenotype, 
has not yet been thoroughly investigated. A number of researches indicated a genetic 
susceptibility of the metabolic syndrome. However, the associations were weak and the 
replication of findings was poor[92], [93]. While the prevalence of the metabolic syndrome 
has increased markedly in the last decades, the human genome has not changed. At present, 
no single gene or cluster of genes has been consistently replicated for the expression of this 
phenotype (metabolic syndrome) among different populations[94], [95], probably due to the 
complex interactions between gene and environment.  
The ‘thrifty genotype’ hypothesis was proposed to explain the emergence of insulin 
resistance and diabetes in populations, shifted from vigorous activity to provide subsistence 
nutrition to sedentary life style with food abundance. In urban societies, the modern 
abundant food environment may be responsible for the elevated insulin levels and excessive 
energy stores in some type 2 diabetic individuals, leading in consequence to insulin 
resistance and obesity[96].  
Genetic background can interact with habitual dietary fat composition, thereby affecting 
predisposition to the metabolic syndrome, and may also determine the individual's 
responsiveness to altered dietary fat intake[97]. Recent research indicates that currently 
ineffective therapeutic dietary recommendations may require a 'personalised nutrition' 
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approach, wherein the genetic profile may determine the responsiveness of patients to 
specific dietary fatty acid interventions[98].  
5.2.2 Socio-economic determinants 
Several prospective observational studies showed that low socio-economic position, 
measured as education level, income, or occupational class was associated with increased 
risk for type 2 diabetes[99] and coronary heart disease[100], [101]. Clinical features of the 
metabolic syndrome were more commonly observed among socio-economically 
disadvantaged individuals[102], in individuals with low education level[103], [104], and in 
those doing menial jobs[105]. There is increasing evidence that the distribution of the 
metabolic syndrome varies among different geographic and socioeconomic categories of the 
population, demonstrating notable health inequalities[106], [107], [108]. 
5.2.3 Behavioural or lifestyle determinants  
Lifestyle choices imposed by modern civilization have been demonstrated to be centrally 
involved in the multi-factorial causation of severe atherosclerotic disease [108]. There has 
been an increasing body of evidence demonstrating that unhealthy behaviours were 
substantially responsible for epidemic prevalence and mortality of cardiovascular disease, 
diabetes and metabolic disorders[4], [5], [109]. In contrast, a healthy lifestyle including non-
smoking, appropriate diet, satisfactory physical activity level and healthy weight provided 
substantial cardiovascular and metabolic benefits[110]. Among the major potentially 
modifiable risk factors for metabolic syndrome and its components are the following: 
1. Smoking  
Growing evidence pointed to smoking as an independent risk factor for metabolic syndrome 
and type 2 diabetes. Smoking is a strong risk factor for atherosclerotic cardiovascular 
disease, with a dose dependent relationship[111], [112]. Several population-based studies 
confirmed that cigarette smoking was independently associated with the metabolic 
syndrome [113], [114], [115], in particular in men[116]. The general belief is that insulin 
resistance or hyperinsulinemia is the main underlying mechanism. Increased insulin 
resistance may underlie the clustering of the metabolic and hemodynamic abnormalities 
that have potential atheroslerotic properties, designated the metabolic syndrome [14]. 
However, this hypothesis still needs to be tested in prospective studies. 
2. Dietary habits  
Although dietary intake has been linked to individual components of the metabolic 
syndrome [117], [118], [119], [97], the role of diet in its origin is not well understood[120]. 
Cross-sectional epidemiological studies demonstrated that dietary intake rich in whole-
grain foods was linked to a lower prevalence of the metabolic syndrome [121], [122], 
although other study found no relation[123]. Dairy intake was inversely associated with the 
metabolic syndrome both prospectively and in cross-sectional studies [124,125]. Greater 
intakes of fruits and vegetables were associated with a lower prevalence of the metabolic 
syndrome [126]. Intakes of soft drinks were also positively associated with the prevalence of 
the metabolic syndrome, but the diet soda-metabolic syndrome incidence association was 
not yet hypothesized and needs further prospective studies [127]. 
www.intechopen.com
 
Cardiometabolic Syndrome 
 
181 
Although various individual foods and nutrients were associated with the development or 
the progression of the metabolic syndrome, only a few studies examined the association 
with dietary patterns[128]. Prospective findings from Atherosclerosis Risk in Communities 
(ARIC) study suggested that consumption of a Western dietary pattern, meat, and fried 
foods promoted the incidence of the metabolic syndrome, whereas dairy consumption 
provided some protection[120].  
Recently, dietary pattern analysis has emerged as an alternative and complementary 
approach to examine the relationship between diet and the risk of chronic diseases. Instead 
of looking at individual nutrients or foods, pattern analysis examines the effects of overall 
diet. Conceptually, dietary patterns address the effect of the diet as a whole and thus may 
provide a broader picture of food and nutrient consumption, and may thus be more 
predictive of disease risk than individual foods or nutrients[129], [130]. 
3. Alcohol consumption 
Across the literature, the association between alcohol consumption and the metabolic 
syndrome is controversial and influenced by several factors, due to broad overlap of alcohol 
consumption with different components of metabolic syndrome. Protective and detrimental 
associations were reported between alcohol consumption and the metabolic syndrome, due 
to variations in drinking patterns and different alcohol effects on the metabolic syndrome 
components[131]. Mild to moderate alcohol consumption is associated with a lower 
prevalence of the metabolic syndrome, with a favourable influence on lipids, waist 
circumference, and fasting insulin. This association was strongest among whites and among 
beer and wine drinkers[132]. 
A recent meta-analysis study, aiming to support the evidence available regarding the 
relationship between alcohol consumption and the metabolic syndrome, as well as to 
identify the gender-specific dose-response, showed that alcohol consumption of less than 40 
g/day in men and 20 g/day in women significantly reduced the prevalence of metabolic 
syndrome [133].  
4. Physical activity 
In agreement with the notion that physical inactivity is a risk factor of diabetes, obesity, 
dyslipidemia and hypertension[134], [135], [136], the prevalence of the metabolic syndrome 
was higher in subjects with poor physical activities[46], [137].  
Sedentary behaviour is an important potential determinant of the metabolic syndrome. 
Several studies demonstrated that physical activity was inversely associated with the 
prevalence of the metabolic syndrome[138], [139], notably among those who spend much 
time in sedentary activity as watching television or video or using a computer[137]. The 
adverse effect of excess television watching on obesity and other cardiovascular risk factors 
is thought to be attributed, in part, to decreased energy expenditure and, in other pat, to 
increased energy intake. Therefore, understanding how sedentary behaviour relates to the 
metabolic syndrome may provide new opportunities for clinical and public health 
approaches in its prevention and control. 
5. Psychosocial factors 
Accumulating evidence implied that psychological mechanisms were possibly underlying the 
development of the metabolic syndrome. The syndrome appeared to be triggered by adverse 
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psycho-social circumstances[140], certain chronic psychological pathologies[141,142] and 
chronic stress[102]. Individuals who had hostile personality and certain behaviour traits, were 
particularly predisposed to develop the metabolic syndrome [102]. Such factors might interact 
with others to encourage the development of metabolic syndrome. The stress is exacerbated by 
lack of social support and/or poor coping skills. As a vicious cycle, the negative psychological 
behaviours may induce unhealthy lifestyle and/or adverse social circumstances[143]. A large 
population study demonstrated a higher incidence of the metabolic syndrome among young 
women, but not in men, with a history of depression after controlling for other associated 
factors [141]. Features of the metabolic syndrome also appeared more common among women 
experiencing social anxiety [144]. These findings suggest the possibility of different gender-
specific causal pathways to the metabolic syndrome development.  
5.2.4 Environmental factors 
Recently, the scientific evidence linking air pollution to heart attacks, strokes and 
cardiovascular death, has been substantially supported, especially for the fine particulate 
matter (PM). The major source of PM is fossil fuel combustion from industry, traffic, and 
power generation. Biomass burning, heating, cooking, indoor activities and forest fires may 
also be relevant sources, particularly in certain regions[145]. 
Several interrelated pathophysiologic mechanisms underlying the observed short-term and 
long-term [146]adverse cardiac effects of ambient air pollution have been elucidated[147], 
for instance, the pivotal role of vascular inflammation in pathogenesis and progression of 
atherosclerosis and coronary heart disease. Systemic inflammatory response to inhaled 
ambient particles has emerged as an important mediator of the PM-associated acute cardiac 
effects[148]. However, human data are still scant and conflicting with respect to the 
pathophysiologic mediators of cardiovascular disease associated with long-term exposure to 
fine PM. Researchers hypothesized that long-term exposure is associated with increased 
systemic inflammation, and that people with metabolic syndrome have a higher degree of 
inflammatory responses to PM. 
5.2.5 Emergent factors 
In a recent research study, a growing number of other factors, called “emerging or novel risk 
factors”, have been described and linked with features of the metabolic syndrome. Several 
new bio-markers or candidate cardiovascular risk factors have been proposed as significant 
predictors of the atherosclerotic disease and its complications. These include inflammatory-, 
hemostasis or thrombosis-, lipid-related markers, oxidative stress, hormonal factors and 
infectious agents [149], [150], [151], [152], [153], [154]. Over the past few years, the concept of 
atherosclerosis as an inflammatory disorder has been substantially established[155]. 
However, the role of systematic inflammation needs further exploration. The novel bio-
markers, psychological and environmental determinants are outside the scope of the present 
chapter and hence will not be further detailed.  
6. Conclusion 
The metabolic syndrome is a multi-factorial disorder and its development is the result of 
interactions between biological, behavioural and environmental factors. Despite 
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disagreement over the relevance and clinical utility of the metabolic syndrome, most 
investigators agree that the clustering of metabolic risk factors is a real and relatively 
common phenomenon[60]. Around the world, the metabolic syndrome is now considered as 
one of the major public health challenges of the 21st century, associated with a 5-fold and 2- 
to 3-fold increase in type 2 diabetes and cardiovascular disease, respectively [32]. In 
consequence, the related premature morbidity and mortality could overcharge the health 
care system budgets of both developed and developing countries[16]. 
The introduction of the metabolic syndrome concept was a stimulus for a large number of 
epidemiological, metabolic, and genetic studies that moved up the scientific research field. 
In addition, the metabolic syndrome constitutes a comprehensive public health message and 
an easily educational tool for patients and health professionals, focusing on the multi-
factorial nature of the atherosclerotic diseases. This approach recommends the same 
prevention and management strategies for both metabolic syndrome and its individual 
components (e.g., a healthy diet, regular physical activities, smoking cessation, weight loss 
and control, plus pharmacological intervention where necessary)[38]. 
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